PO-02-240 IMPACTS OF DAPAGLIFLOZIN ON STRUCTURAL REMODELING AND ARRHYTHMOGENICITY IN CARDIORENAL SYNDROME

Chronic kidney disease (CKD) patients revealed cardiac structural and electrical remodeling. The interaction between the heart leads to cardiorenal syndrome. Dapagliflozin (DAPA) reduces cardiovascular (CV) events in failure (HF). However, efficacy of DAPA on syndrome is questionable. We aimed investigate electrophysiology (EP) properties reverse remodeling dapagliflozin CKD rabbits with HF. Eighteen New Zealand white were randomized into sham (n=6), CKD-DAPA (n=6) groups. groups created by 5/6 nephrectomy method follow-up echocardiogram confirm group received oral 1 mg/kg/day for 4 weeks. All an echocardiogram, blood samples, EP study. Myocardium was harvested Trichrome stain. creatinine levels significantly higher than those (2.31±0.21 vs. 1.32±0.11 mg/dL; 2.29±0.13 mg/dL, both p<0.01), respectively. showed a reduced left ventricular ejection fraction when compared (47.4±0.81 53.3±1.47 %; 48.41±1.50, Baseline rhythm sinus all no spontaneous arrhythmias found. RR interval longer (Figure A). effective refractory period (ERP) chambers difference among 3 groups, respectively B). In atrial inducibility test, 2 inducible arrhythmia. arrhythmia (VA). had VA (32.00±10.95 0.00±0.00 %, p<0.001) larger area fibrotic tissue C). Figure D demonstrated collagen deposition (blue) myocardium led decreased reversed rabbits. potentially risk arrhythmogenicity